Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC43 recombinant Pseudomonas vaccine in mechanically ventilated ICU patients
2011-004771-36Phase 2Completed
- Sponsor
- Valneva
- Start
- Dec 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Pseudomonal infection comparing IC43 vaccine with Placebo (2 arms). Primary endpoint: Day 28 all-cause mortality. Started Dec 2011; status: completed.
02
Drugs
IC43
03
Conditions
Pseudomonal infection
Beyond the preview
Go deeper on 2011-004771-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004771-36.